Results
Percutaneous coronary intervention (PCI) is the most commonly performed method for coronary revascularization in the United States (US). 1 Intracoronary thrombosis plays a central role in complications that occur during and after PCI. 2 Inhibition of platelet aggregation is important to prevent of thrombotic complications. Current guidelines recommend use of antiplatelet agents in combination with anti-thrombin agents for PCI. 3 Cangrelor is a novel, intravenous (IV), non-thienopyridine antagonist of the P2Y 12 receptor. Platelet inhibition occurs immediately upon cangrelor administration; normal platelet activity resumes within 60 minutes of drug discontinuation. 4 The predictable pharmacokinetic (PK) profile and quick onset of action allow for increased flexibility, enabling physicians to rapidly terminate inhibition for surgery or slowly taper off administration for transition to an oral P2Y 12 . Randomized clinical studies of cangrelor have been conducted in more than 25,000 individuals undergoing PCI. The recent Phase III CHAMPION PHOENIX trial demonstrated that cangrelor has superior efficacy compared with clopidogrel in the setting of PCI with a significant 22% reduction in the rate of death, myocardial infarction (MI), ischemia-driven revascularization (IDR) and stent thrombosis (ST) at 48 hours and a significant 38% reduction of ST. 5 The CHAMPION PHOENIX trial demonstrated that cangrelor significantly reduced procedural and post-PCI thrombotic events, yet the economic benefits of preventing such events are not well known. A PHOENIX sub-study (PHOENIX ECONOMICS Study: An economic study to estimate the cost of intra-procedural thrombotic events in a dataset of percutaneous coronary intervention patients receiving cangrelor or clopidogrel) was designed to 1) estimate the incremental costs and healthcare resource utilization (HRU) of procedural complications; 2) examine the differences in HRU and costs between cangrelor and clopidogrel treatment in the US, which is the focus of this analysis. The costs for patients treated with cangrelor plus heparin or clopidogrel plus bivalirudin were also analyzed. Due to the limitation of randomized clinical trial design, present analysis addresses just one component of the potential cost-savings attributable to the adoption of cangrelor in PCI. Economic modelling suggests that hospitals adopting cangrelor in acute coronary syndrome (ACS) patients undergoing PCI could realize cost savings by eliminating the scenario in which patients who have received an oral P2Y 12 inhibitor require a coronary artery bypass graft surgery (CABG) and further analyses are necessary to quantify the potential cost savings as a result of reduction in use of glycoprotein IIb/IIIa inhibitors (GPI), both in terms of drug acquisition and administration costs.
Methods
 A total of 1,117 patients (27.3% of 4,097 PHOENIX US population) and their hospital bills from 21 study sites were collected and analyzed (Figure 1 ).
 The PHOENIX ECONOMICS sample was comparable to the CHAMPION PHOENIX US population (Tables 1 and 2 ).
-The selected patient demographics and medical history were similar clinically between two populations even though some differences were observed statistically. -Most notably, the distribution of stable angina, NSTE-ACS and STEMI was nearly identical.
-Most of the 48-hour ischemic event rates and bleeding incidences differed significantly between PHOENIX ECONOMICS sample and the CHAMPION PHOENIX US population. ACUITY minor bleeding rates were lower and GUSTO mild bleeding rates were higher for the PHOENIX ECONOMICS sample.
 Randomization from the CHAMPION PHOENIX trial was maintained in the PHOENIX ECONOMICS study, as evidenced by the equal distribution of 560 cangrelor-and 557 clopidogrel-treated patients (Table 1) .
 The PHOENIX ECONOMICS sample showed that there were numerical differences (NS) of costs between two treatment groups. The similar finding was observed in the subgroup of patients receiving bivalirudin (Table 3 ).
 Results from the MICE simulation showed a decrease of $158.86 (NS) in index hospitalization costs and $109.11 (NS) in cath lab costs with cangrelor treatment compared with clopidogrel treatment for the entire CHAMPION PHOENIX US study population (Table 4) . Similarly, in the bivalirudin subgroup, the index hospitalization cost of cangrelor was numerically $274.71 less than that of clopidogrel patients and the cath lab cost of cangrelor was numerically $91.61 less.
Figure 1. Exclusions from PHOENIX ECONOMICS Analysis
Study Design and Conduct:
 PHOENIX ECONOMICS was a non-interventional, retrospective bill collection and analysis study. It involved a subset of US patients enrolled in the CHAMPION PHOENIX trial.
 All 38 US sites enrolled in the CHAMPION PHOENIX trial and had at least one procedural complications were invited to participate in this economic sub-study and 22 agreed to participate.
 HIPAA-waivers and IRB approvals were obtained at each institution.  Paper bills were collected by certified clinical research associates and were redacted for any patient, hospital or insurance payer's identifying information.
 Hospital costs were determined by multiplying itemized hospital charges and the cost-center specific cost-to-charge ratio (CCR) obtained from hospital's Medicare cost report.  The billing dataset was then combined with clinical data from the CHAMPION PHOENIX trial to obtain the demographic and baseline characteristics, PCI procedural information, and all complication events patients experienced.
Study Population:
The clinical inclusion and exclusion criteria for the PHOENIX ECONOMICS study mirrored those of the CHAMPION PHOENIX trial. 5 Additional inclusion criteria for economic study consisted of the following:  Patients enrolled in the CHAMPION PHOENIX trial, underwent PCI, and received one of the two study drugs;  Patients enrolled in one of 22 participating PHOENIX ECONOMICS US study sites; and  Patients with complete hospital billing records -hospitalization bill line items were complete in term of charges, without double billing records, inconsistent coding, and/or missing charge descriptions; -PCI charges were represented in bills; and, -The site had complete departmental cost-to-charge ratios on file.
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Statistical Analysis:
 Univariate analyses to compare the PHOENIX ECONOMICS study population with the CHAMPION PHOENIX US mITT population with respect to patient baseline characteristics and 48-hour event rates were conducted to examine the representativeness of PHOENIX ECONOMICS study population.
 The cangrelor and clopidogrel treatment groups from the PHOENIX ECONOMICS study population were also evaluated to identify any differences in patient demographics or medical history.
 Index-hospital costs and catheterization laboratory costs were compared between treatment groups.
 Statistical significance was assessed using Chi-square and Wilcoxon Sum-Rank tests for categorical and continuous variables respectively, at a significance level of P<0.05. No adjustment was made for multiple comparisons due to the exploratory nature of the study design.
Sensitivity Analysis:
Given the fact that the PHOENIX ECONOMICS study population was a subset of the CHAMPION PHOENIX US study population, it was expected that results for the US population would be similar. A sensitivity analysis was performed on the entire CHAMPION PHOENIX US population.
 A regression-based multiple imputation by chained equations (MICE) method was utilized to project the missing cost for the CHAMPION PHOENIX US patients who were not part of the PHOENIX ECONOMICS population.

Step 1: 20 cycles were repeated to stabilize and produce a single imputed dataset  Step 2: 70 imputed datasets were yielded by repeating the
Step 1 independently  With 70 imputed datasets, the cost differences between cangrelor and clopidogrel were re-analyzed among entire PHOENIX US population. The differences and standard errors were averaged over the 70 imputed datasets.
 The total costs and two-sided 95% confidence intervals (CI) of the difference between costs for cangrelor and clopidogrel were calculated among PHOENIX ECONOMICS study population.
 The results were compared with the results from ECONOMICS population for consistency and stability.
All summaries and statistical analyses were generated using SAS ® version 9.2 (SAS Inc., NC, USA) and STATA ® version 12 (StatCorp, TX, USA). BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure; MI, myocardial infarction; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; SA, stable angina; SD, standard deviation; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischemic attack 
